Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or ...

In a new study published in Nature, researchers from the Massachusetts Institute of Technology (MIT) showcased engineered prime editors with significantly lower rates of indel formation. “This paper ...

For babies born with alternative hemiplegia of childhood (AHC), an extremely rare and severe neurodevelopmental disorder, there may be no obvious symptoms for several months. Then the attacks begin: ...

Since the development of the base and prime editing technique by David Liu at the Broad Institute, their applications in biomedicine have continued to grow, reaching 17 clinical trials for base ...

Prime Medicine announces promising preclinical results for a novel AATD treatment using advanced Prime Editing technology, aiming for clinical trials by mid-2026. Prime Medicine, Inc. announced the ...

The biotechnology firm Prime Medicine is approaching what could be its most definitive period. Following its 2025 annual results, the company is shifting its strategic emphasis from initial clinical ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...

Prime Medicine (NASDAQ: PRME) has had a lot to celebrate in recent months, explaining a surge that has seen the prime editing therapy developer’s stock more than double this year, including a 22% jump ...